The combined use of statin and rapamycin treatments synergistically inhibit the proliferation of B cell Lymphoma.

---

Presentation Time: 11:30 AM - 12:45 PM
Poster Board Number: B955
Abstract ID: 5414

Presenting Author:
Zhenhan Zhu , Student at Indiana Univ. Sch. of Med.

Abstract:

Sterol Regulatory Element-Binding Protein (SREBP) signaling plays a crucial role in maintaining sterol homeostasis during B cell activation and the proliferation of germinal center B cells. It is unclear whether this pathway can be targeted to effectively treat B cell lymphoma. We discovered that inhibiting SREBP signaling or its downstream target 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) using Fatostatin or Simvastatin effectively restrains the proliferation of B cell lymphoma cells. However, B cell lymphoma cells activate the mTORC1-pS6 pathway in response to statin treatment, suggesting a possible mechanism to counteract statin-induced cell cycle arrest. Combining statin treatment with the mTOR inhibitor rapamycin demonstrates a synergistic effect in inhibiting B cell lymphoma proliferation, impeding cell cycle progression, and regulating sterol production. These findings emphasize the potential of a combined therapy approach targeting both SREBP and mTORC1 as a treatment strategy for B cell lymphoma.